Armodafinil

阿莫达非尼

Report date: 2026/03/30 17:02:26

Base Information

Drug NameArmodafinil
Drug Alias NameArmodafinilum阿莫非尼阿莫达非ArmodafiniloR-modafinil +[9] 
ClassificationSmall molecules
Mechanisms of ActionDopamine receptors antagonistsDopamine transporter antagonists
TargetsDopamine transporterDopamine receptors
Therapy Area/IndicationsBipolar I DisorderSchizophreniaCognition Disorders +[28] 
Global Approved IndicationsDisorders of Excessive Somnolence
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2007/06/15
Country/TerritoryBulgariaCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTeva Pharmaceutical Industries Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterNuvo Pharmaceuticals Inc
Inactive CompaniesUniversity of Texas Southwestern Medical CenterWake Forest University Health SciencesUniversity Of Rochester +[13] 
Active IndicationsFatigueDisorders of Excessive SomnolenceHead and Neck Neoplasms
Inactive IndicationsBipolar I DisorderSchizophreniaCognition Disorders +[25] 

Other Information

ATC CodeN06BA13
Related LinksWikipediaDrugBankKEGG